Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001193125-25-233666
Filing Date
2025-10-07
Accepted
2025-10-07 17:22:26
Documents
2
Period of Report
2025-10-06

Document Format Files

Seq Description Document Type Size
1 3 ownership.html 3  
1 3 ownership.xml 3 2229
2 EX-24 phat-ex24.htm EX-24 12622
  Complete submission text file 0001193125-25-233666.txt   16321
Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Issuer) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address C/O INTRA-CELLULAR THERAPIES, INC. 135 ROUTE 202/206 BEDMINSTER NJ 07921
Business Address
Narula Sanjeev (Reporting) CIK: 0001820590 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-39094 | Film No.: 251380664